文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

两种COVID-19相关急性呼吸窘迫综合征表型低氧血症的病理机制:血栓形成与止血的启示

Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.
PubMed 文献 · Shock · 2022-01-01
一句话结论H型ARDS低氧血症由弥漫性肺泡损伤所致右向左分流引起,L型由肺微血管免疫血栓形成导致高通气/血流比值引起;基于D-二聚体监测的抗凝治疗可能预防和/或减轻ARDS进展。

本文综述SARS-CoV-2诱导的COVID-19中H型和L型ARDS低氧血症的病理机制及治疗策略。SARS-CoV-2主要靶向肺和血液,导致ARDS及全身性血栓形成或出血;血管紧张素II诱导的凝血病、SARS-CoV-2诱导的高纤维蛋白(原)溶解以及免疫血栓形成所致的肺和/或弥散性血管内凝血共同参与COVID-19相关凝血病。H型ARDS的低氧血症源于弥漫性肺泡损伤所致高右向左分流;L型ARDS中肺微血管内中性粒细胞胞外诱捕网含血小板和纤维蛋白,导致血流受损和高通气/血流比值而致低氧血症。COVID-19相关ARDS较其他类型ARDS更以血管为中心;D-二聚体水平已被监测用于COVID-19患者微血管血栓进展;对D-二聚体水平高的危重患者早期抗凝治疗可能改善预后,包括预防和/或减轻ARDS。

要点

  • H型ARDS低氧血症由弥漫性肺泡损伤所致高右向左分流引起。
  • L型ARDS低氧血症由肺微血管免疫血栓形成(中性粒细胞胞外诱捕网含血小板和纤维蛋白)导致血流受损和高通气/血流比值引起。
  • COVID-19相关ARDS较其他类型ARDS更以血管为中心。
  • D-二聚体水平已被监测用于COVID-19患者微血管血栓进展。
  • 对D-二聚体水平高的危重患者早期抗凝治疗可能改善预后,包括预防和/或减轻ARDS。

适用人群与场景

  • SARS-CoV-2诱导的COVID-19患者,表现为H型或L型ARDS。

处置流程与药物剂量

  • 对D-二聚体水平高的危重患者早期抗凝治疗可能改善预后,包括预防和/或减轻ARDS(原文未给出具体药物、剂量、途径、频次或目标值)。

研究设计与关键结果

  • SARS-CoV-2主要靶向肺和血液,导致ARDS及全身性血栓形成或出血。
  • 血管紧张素II诱导的凝血病、SARS-CoV-2诱导的高纤维蛋白(原)溶解以及免疫血栓形成所致的肺和/或弥散性血管内凝血共同参与COVID-19相关凝血病。
  • H型ARDS低氧血症由弥漫性肺泡损伤所致高右向左分流引起。
  • 免疫血栓形成发生于感染部位,由对SARS-CoV-2的先天免疫炎症和凝血纤溶反应所致,导致微血管闭塞和肺低灌注。
  • L型ARDS中肺免疫血栓形成由肺微血管内中性粒细胞胞外诱捕网含血小板和纤维蛋白所致,导致血流受损和高通气/血流比值而致低氧血症。
  • COVID-19相关ARDS较其他类型ARDS更以血管为中心。
  • D-二聚体水平已被监测用于COVID-19患者微血管血栓进展。
  • 对D-二聚体水平高的危重患者早期抗凝治疗可能改善预后,包括预防和/或减轻ARDS。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,右向左分流和高通气/血流比值分别由肺微血管血栓形成所致,参与H型和L型ARDS的低氧血症。
  • 作者认为,基于D-二聚体监测的抗凝治疗可能预防和/或减轻COVID-19患者ARDS的进展和/或恶化。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The pathomechanisms of hypoxemia and treatment strategies for type H and type L acute respiratory distress syndrome (ARDS) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19) have not been elucidated.

MAIN TEXT: SARS-CoV-2 mainly targets the lungs and blood, leading to ARDS, and systemic thrombosis or bleeding. Angiotensin II-induced coagulopathy, SARS-CoV-2-induced hyperfibrin(ogen)olysis, and pulmonary and/or disseminated intravascular coagulation due to immunothrombosis contribute to COVID-19-associated coagulopathy. Type H ARDS is associated with hypoxemia due to diffuse alveolar damage-induced high right-to-left shunts. Immunothrombosis occurs at the site of infection due to innate immune inflammatory and coagulofibrinolytic responses to SARS-CoV-2, resulting in microvascular occlusion with hypoperfusion of the lungs. Lung immunothrombosis in type L ARDS results from neutrophil extracellular traps containing platelets and fibrin in the lung microvasculature, leading to hypoxemia due to impaired blood flow and a high ventilation/perfusion (VA/Q) ratio. COVID-19-associated ARDS is more vascular centric than the other types of ARDS. D-dimer levels have been monitored for the progression of microvascular thrombosis in COVID-19 patients. Early anticoagulation therapy in critical patients with high D-dimer levels may improve prognosis, including the prevention and/or alleviation of ARDS.

CONCLUSIONS: Right-to-left shunts and high VA/Q ratios caused by lung microvascular thrombosis contribute to hypoxemia in type H and L ARDS, respectively. D-dimer monitoring-based anticoagulation therapy may prevent the progression to and/or worsening of ARDS in COVID-19 patients.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Gando S, Wada T. Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis. Shock. 2022. PMID: 34172612. doi:10.1097/SHK.0000000000001825

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。